Appili Therapeutics Inc. (APLI.TO)
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0500 x N/A |
| Ask | 0.0550 x N/A |
| Day's Range | 0.0500 - 0.0500 |
| 52 Week Range | 0.0350 - 0.1700 |
| Volume | |
| Avg. Volume | 251,405 |
| Market Cap | 6.063M |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4140 |
| Earnings Date | Feb 13, 2023 - Feb 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.30 |
- Business Wire
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
HALIFAX, Nova Scotia, January 17, 2023--Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Francisella tularensis, whi
- Baystreet
Stocks in play: Appili Therapeutics Inc.
Announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance ...
- Business Wire
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
HALIFAX, Nova Scotia, January 13, 2023--Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole. A notice of allowance is issued by the USPTO to indicate that t
